Product Description
Letermovir is used to help prevent cytomegalovirus (CMV) infection and disease in certain people who have received a hematopoietic stem-cell transplant (HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow) and are at increased risk of developing a CMV infection. Letermovir is in a class of medications called antivirals. It works by slowing the growth of CMV. (Sourced from: https://medlineplus.gov/druginfo/meds/a618006.html)
Mechanisms of Action: CMV Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Colombia | Croatia | Czech | Denmark | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: Allogeneic Stem Cell Transplant | Hematopoietic Stem Cell Transplant | Stem Cell Transplant
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Diarrhea | Edema
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Canada, China, Colombia, France, Germany, Hungary, Israel, Italy, Japan, Mexico, New Zealand, Poland, Spain, Turkey, United Kingdom, United States
Active Clinical Trial Count: 21
Highest Development Phases
Phase 3: Allogeneic Stem Cell Transplant|Communicable Diseases|Cytomegalovirus Infections|Hematopoietic Stem Cell Transplant|Kidney Diseases|Kidney Transplant|Pancreas Transplant|Renal Transplant
Phase 2: Acquired Immunodeficiency Syndrome|Chronic Lymphoid Leukemia|HIV Infections|Heart Transplant|Inflammation|Lung Transplant|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Prolymphocytic B-Cell Leukemia|Prolymphocytic Leukemia|Prolymphocytic T-Cell Leukemia|Sezary Syndrome|T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma|Transplantation Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LETERCOR | P2 |
Not yet recruiting |
Cytomegalovirus Infections|Communicable Diseases |
2027-04-01 |
|
| A561000 | P3 |
Recruiting |
Communicable Diseases|Pancreas Transplant|Cytomegalovirus Infections|Kidney Diseases|Kidney Transplant |
2026-09-01 |
|
| NCT06066957 | P2 |
Recruiting |
Transplantation Unspecified|Cytomegalovirus Infections |
2026-08-15 |
|
| Cypher-TX Pilot | P2 |
Active, not recruiting |
Heart Transplant |
2026-05-23 |